

OIE Reference Laboratory annual reports (RINDERPEST)

Activities in 2021

Name (including Title) of Head of Laboratory (Responsible Official): Dr. Ken Katsuda, Director, National Institute of Animal Health

Name (including Title and Position) of OIE Reference Expert: Dr. Takehiro Kokuho, Director, Division of Transboundary Infectious Animal Disease Research

Email address: takehiro@affrc.go.jp

Address of laboratory: Josuihoncho 6-20-1, Kodaira, Tokyo, Japan

Website: <https://www.naro.go.jp/english/laboratory/niah/index.html>

Telephone: +81-42 321.14 40 Fax: +81-42 325.5122

A: Maintaining Scientific and Technical Skills

1. Did your laboratory perform relevant diagnostic tests for purposes such as disease, diagnosis, screening of animals for export, surveillance, etc. (not for quality control, proficiency testing or staff training)
 - a. For the specified disease?
 - b. For closely related diseases or pathogens?

Disease	Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year	
			Nationally	Internationally
NA				

2. Did your laboratory produce, supply, or import standard reference reagents officially recognised by the OIE for the specified disease or for closely related diseases?

Type of Reagent Available	Related diagnostic test	Produced/Supplied/Imported	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	Name of recipient OIE member countries
NA					

3. Did your laboratory supply, exchange or receive standard reference reagents and/or other diagnostic reagents for the specified disease

Type of reagent	Related diagnostic test	Supplied by your lab, exchanged or received	Amount	Name of recipient or supplier member country
NA				

4. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country for the specified disease or for closely related diseases?

Name of the OIE member country receiving the technical consultancy	Purpose	How the advice was provided
NA		

5. What method of dissemination of information is most often used by your laboratory? (please provide information on activities for other diseases relevant to maintaining capability for specified disease) [a: Articles published in peer-reviewed journals; b: International conferences; c: National conferences; d: Other]

a: Articles published in peer-reviewed journals, and b: International conferences

6. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

No

7. Did your laboratory implement activities to ensure ongoing capability for the designated disease or closely related disease in the event of loss of the key staff including the OIE Reference Expert?

Activity	Description
Proficiency testing for the diagnosis	Performing sham testing for the diagnosis of rinderpest using related viruses based on the ISO accredited method
Capacity building for the production of vaccines	Educate new staff for the production of rinderpest vaccines by experienced personnel with approval of FAO and OIE.

B: Laboratory Systems

8. Does your laboratory have a Quality Management System certified according to an International Standard? If YES indicate the name of the quality management system adopted or currently in place. Also attach a scanned certificate of the system.

ISO17025

9. Is your laboratory accredited by an international accreditation body? If 'yes' indicate test for which your laboratory is accredited and name of the accreditation body.

Yes

Diagnosis for rinderpest, classical swine fever, Foot-and-mouth disease, Influenza A, Prion diseases
Japan Accreditation Board (JAB)

10. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

No

11. Does your laboratory have a biosecurity system in place to ensure security for the pathogen and materials that may contain the infectious pathogen?

Yes

No

C: Capability to Respond to a Suspected Case

12. In the last year, did your laboratory perform diagnostic tests for the specified pathogen and the disease in order to confirm ongoing capability?

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of tests performed last year
Proficiency testing for the diagnosis of rinderpest (sham testing)	No	7

13. Did your laboratory produce vaccines for the specified disease or similar diseases?

Disease	Amount supplied nationally or internationally
Rinderpest (LA-AKO), final products	100,000 doses (domestic) and 763,600 doses (international)

14. Did your laboratory organise or participate in inter-laboratory proficiency tests with any other laboratories for the specified disease or similar diseases?

Role of your laboratory (organiser or participant)	Disease	Test	Number of participating laboratories	Regions of participating OIE member countries
NA				

D: Networks and Linkages

15. Did your laboratory organise or participate in scientific meetings for the specified disease?

Title of event	Date	Location	Role (Organiser, speaker, presenter)	Title of work presented
Rinderpest holding facility network teleconference	May 18 Dec 12	web	participant	
OIE RL regional meeting	Dec 3	web	participant	

16. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes
 No

17. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease?

Yes
 No

18. Did your laboratory place expert consultants at the disposal of the OIE?

Yes
 No

19. Did your laboratory carry out activities to raise awareness and improve capability for this disease in other member countries?

Description of activity	Date	Member countries
NA		

E: Biosafety

20. What level of biocontainment is used in your laboratory for (a) storage and (b) handling of potentially infectious material for the specified disease?

Kodaira, Tokyo (RHF category A): (a) BSL3, (b) BSL3
Tsukuba, Ibaraki (RHF category B): (a) BSL2, (b) BSL2

21. Does your laboratory maintain a structured risk assessment for work with potentially infectious material for the specified disease?

Yes

No

22. Was your laboratory's risk assessment for work with potentially infectious material reviewed in the past year?

Yes

No

23. Does your laboratory have an emergency response plan for biosafety incidents involving potentially infectious material for the specified disease?

Yes

No

F: Research

24. Did your laboratory develop new diagnostic methods for the designated pathogen or disease, or a similar disease?

Disease	Diagnostic Method	Description
NA		

25. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than your own?

Title of study	Duration	Purpose of study	Partners (Institutions)	OIE Member Countries Involved other than your Country
MOU (extended)	Mar, 2017- Mar, 2027	Studies on the immune responses of animal infectious diseases	National Institute of Veterinary Research	Vietnam

26. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest or a similar pathogen?

Title of Project or Contract	Scope	Name(s) of relevant OIE Reference Laboratories
NA		

27. Additional comments regarding your report (if any):